Also, SGLT-2 inhibitors were not administered for HF in this group, because approval for this medication to treat patients suffering from heart failure with reduced ejection fraction (HFrEF) was granted in late 2020. This evidence concerns the gene SLC5A2 and hydrops fetalis.